Filing Flows › Tvardi Therapeutics (TVRD) › Recalls, complaints & regulation
Tvardi Therapeutics (TVRD): clinical trials
Tvardi Therapeutics (TVRD) beyond its filings: 1 active clinical trial.
Tvardi Therapeutics' latest quarter
Tvardi Therapeutics, Q1 2025: revenue $2.6M (+20% year over year), operating margin -92.9%, net loss $4.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
How many clinical trials does Tvardi Therapeutics have?
1 active study on ClinicalTrials.gov, 0 in phase 3.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.